274 related articles for article (PubMed ID: 32805923)
1. Combination of Nucleic Acid and Mesoporous Silica Nanoparticles: Optimization and Therapeutic Performance In Vitro.
Juneja R; Vadarevu H; Halman J; Tarannum M; Rackley L; Dobbs J; Marquez J; Chandler M; Afonin K; Vivero-Escoto JL
ACS Appl Mater Interfaces; 2020 Sep; 12(35):38873-38886. PubMed ID: 32805923
[TBL] [Abstract][Full Text] [Related]
2. Integrated hollow mesoporous silica nanoparticles for target drug/siRNA co-delivery.
Ma X; Zhao Y; Ng KW; Zhao Y
Chemistry; 2013 Nov; 19(46):15593-603. PubMed ID: 24123533
[TBL] [Abstract][Full Text] [Related]
3. A cationic amphiphilic co-polymer as a carrier of nucleic acid nanoparticles (Nanps) for controlled gene silencing, immunostimulation, and biodistribution.
Halman JR; Kim KT; Gwak SJ; Pace R; Johnson MB; Chandler MR; Rackley L; Viard M; Marriott I; Lee JS; Afonin KA
Nanomedicine; 2020 Jan; 23():102094. PubMed ID: 31669854
[TBL] [Abstract][Full Text] [Related]
4. Targeted delivery of doxorubicin to mitochondria using mesoporous silica nanoparticle nanocarriers.
Qu Q; Ma X; Zhao Y
Nanoscale; 2015 Oct; 7(40):16677-86. PubMed ID: 26400067
[TBL] [Abstract][Full Text] [Related]
5. Folate/N-acetyl glucosamine conjugated mesoporous silica nanoparticles for targeting breast cancer cells: A comparative study.
Kumar P; Tambe P; Paknikar KM; Gajbhiye V
Colloids Surf B Biointerfaces; 2017 Aug; 156():203-212. PubMed ID: 28531877
[TBL] [Abstract][Full Text] [Related]
6. Redox-responsive mesoporous silica nanoparticles: a physiologically sensitive codelivery vehicle for siRNA and doxorubicin.
Ma X; Teh C; Zhang Q; Borah P; Choong C; Korzh V; Zhao Y
Antioxid Redox Signal; 2014 Aug; 21(5):707-22. PubMed ID: 23931896
[TBL] [Abstract][Full Text] [Related]
7. Enhancing Cellular Uptake and Doxorubicin Delivery of Mesoporous Silica Nanoparticles via Surface Functionalization: Effects of Serum.
Shahabi S; Döscher S; Bollhorst T; Treccani L; Maas M; Dringen R; Rezwan K
ACS Appl Mater Interfaces; 2015 Dec; 7(48):26880-91. PubMed ID: 26562468
[TBL] [Abstract][Full Text] [Related]
8. Poly(amidoamine)-modified mesoporous silica nanoparticles as a mucoadhesive drug delivery system for potential bladder cancer therapy.
Wang B; Zhang K; Wang J; Zhao R; Zhang Q; Kong X
Colloids Surf B Biointerfaces; 2020 May; 189():110832. PubMed ID: 32070865
[TBL] [Abstract][Full Text] [Related]
9. A strategy using mesoporous polymer nanospheres as nanocarriers of Bcl-2 siRNA towards breast cancer therapy.
Wu X; Zheng Y; Yang D; Chen T; Feng B; Weng J; Wang J; Zhang K; Zhang X
J Mater Chem B; 2019 Jan; 7(3):477-487. PubMed ID: 32254735
[TBL] [Abstract][Full Text] [Related]
10. In Situ Synthesis of Ultrathin ZIF-8 Film-Coated MSNs for Codelivering Bcl 2 siRNA and Doxorubicin to Enhance Chemotherapeutic Efficacy in Drug-Resistant Cancer Cells.
Pan QS; Chen TT; Nie CP; Yi JT; Liu C; Hu YL; Chu X
ACS Appl Mater Interfaces; 2018 Oct; 10(39):33070-33077. PubMed ID: 30203954
[TBL] [Abstract][Full Text] [Related]
11. Induction of Cytokines by Nucleic Acid Nanoparticles (NANPs) Depends on the Type of Delivery Carrier.
Avila YI; Chandler M; Cedrone E; Newton HS; Richardson M; Xu J; Clogston JD; Liptrott NJ; Afonin KA; Dobrovolskaia MA
Molecules; 2021 Jan; 26(3):. PubMed ID: 33513786
[TBL] [Abstract][Full Text] [Related]
12. Engineered design of mesoporous silica nanoparticles to deliver doxorubicin and P-glycoprotein siRNA to overcome drug resistance in a cancer cell line.
Meng H; Liong M; Xia T; Li Z; Ji Z; Zink JI; Nel AE
ACS Nano; 2010 Aug; 4(8):4539-50. PubMed ID: 20731437
[TBL] [Abstract][Full Text] [Related]
13. Mesoporous Silica Nanoparticles as Carriers for Intracellular Delivery of Nucleic Acids and Subsequent Therapeutic Applications.
Cha W; Fan R; Miao Y; Zhou Y; Qin C; Shan X; Wan X; Li J
Molecules; 2017 May; 22(5):. PubMed ID: 28492505
[TBL] [Abstract][Full Text] [Related]
14. Macroporous silica nanoparticles for delivering Bcl2-function converting peptide to treat multidrug resistant-cancer cells.
Xu W; Ge P; Niu B; Zhang X; Liu J; Xie J
J Colloid Interface Sci; 2018 Oct; 527():141-150. PubMed ID: 29787950
[TBL] [Abstract][Full Text] [Related]
15. Mesoporous silica nanoparticle nanocarriers: biofunctionality and biocompatibility.
Tarn D; Ashley CE; Xue M; Carnes EC; Zink JI; Brinker CJ
Acc Chem Res; 2013 Mar; 46(3):792-801. PubMed ID: 23387478
[TBL] [Abstract][Full Text] [Related]
16. Co-Delivery of Epirubicin and siRNA Using Functionalized Mesoporous Silica Nanoparticles Enhances In vitro and In vivo Drug Efficacy.
Hanafi-Bojd MY; Jaafari MR; Ramezanian N; Abnous K; Malaekeh-Nikouei B
Curr Drug Deliv; 2016; 13(7):1176-1182. PubMed ID: 26718488
[TBL] [Abstract][Full Text] [Related]
17. Hybrid silica-coated Gd-Zn-Cu-In-S/ZnS bimodal quantum dots as an epithelial cell adhesion molecule targeted drug delivery and imaging system.
Akbarzadeh M; Babaei M; Abnous K; Taghdisi SM; Peivandi MT; Ramezani M; Alibolandi M
Int J Pharm; 2019 Oct; 570():118645. PubMed ID: 31465835
[TBL] [Abstract][Full Text] [Related]
18. Recent applications of the combination of mesoporous silica nanoparticles with nucleic acids: development of bioresponsive devices, carriers and sensors.
Castillo RR; Baeza A; Vallet-Regí M
Biomater Sci; 2017 Feb; 5(3):353-377. PubMed ID: 28105473
[TBL] [Abstract][Full Text] [Related]
19. Assessment of Intracellular Compartmentalization of RNA Nanostructures.
Radwan Y; Afonin KA; Johnson MB
Methods Mol Biol; 2023; 2709():211-228. PubMed ID: 37572283
[TBL] [Abstract][Full Text] [Related]
20. Synthesis of lactoferrin mesoporous silica nanoparticles for pemetrexed/ellagic acid synergistic breast cancer therapy.
Ali OM; Bekhit AA; Khattab SN; Helmy MW; Abdel-Ghany YS; Teleb M; Elzoghby AO
Colloids Surf B Biointerfaces; 2020 Apr; 188():110824. PubMed ID: 32023511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
